Thyroid Disease

First Treatment for Thyroid Eye Disease Gets FDA Approval

The Food and Drug Administration (FDA) has approved Tepezza™ (teprotumumab-trbw; Horizon Therapeutics) for the treatment of thyroid eye disease. Tepezza™, a fully human monoclonal antibody, works by binding to insulin-like growth factor 1 receptor and blocking its activation and signaling. The treatment is administered as an intravenous infusion. The approval of Tepezza™ was supported by…

FDA: Thyroid Medications Recalled Due to Inconsistent Potency

Westminster Pharmaceuticals announced a recall of all lots of Levothyroxine and Liothyronine (Thyroid Tablets) 15mg, 30mg, 60mg, 90mg, 120mg as the product was manufactured using active pharmaceutical ingredients (API) from a company that was found to have deviated from the Food and Drug Administration (FDA)’s Good Manufacturing Practices. FDA laboratory tests confirmed Sichuan Friendly Pharmaceutical’s…

Thyroidectomy Rates Lower After Guideline Implementation

Researchers found that up-front total thyroidectomy was performed in 61% of patients before the 2015 American Thyroid Association guidelines were implemented and in 31.4% after guideline implementation (odds ratio [OR], 0.29).